

Help

Bloomberg

## Company In Depth Fundamentals - Profile

Ticker: **JNJ US EQUITY**

**Johnson & Johnson (New York: JNJ, Currency: USD)**

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Website: www.jnj.com  
 Number of Employees: 144,300  
 Ticker: JNJ US


1 Johnson & Johnson Plaza New Brunswick, NJ 08933 United States  
 Phone : 1-732-524-0400  
 Fax : --

↓ **177.03** -0.65 (-0.37%)

Johnson & Johnson fabrica productos de sanidad y provee servicios relacionados para los mercados de consumo, farmacéuticos, dispositivos médicos y de diagnósticos. Vende productos de piel y cabello, acetaminofénicos, farmacéuticos, equipo de diagnóstico y de cirugía alrededor del mundo.

**Stock Quote & Chart (Currency: USD)**

Last (delayed quote)	177.03	Market Cap (MM)	462,842.0
Open	176.77	Shares Out. (MM)	2,614.5
Previous Close	177.68	Float %	99.9%
Change	2.01	Shares sold short (MM)	12,871,010.0
Change %	1.14	Dividend Yield %	2.5
Day High/Day Low	177.5 / 175.3	Diluted EPS Excl. XO	
52 Wk High/52 Wk low	186.7 / 155.7	P / Diluted EPS Before XO	
Volume (MM)	5.71	Beta	0.57
Avg. Vol - 3 mo (MM)	6.96		



**Financial Information (Currency: USD, in mm)**

Revenue - LTM	96,041.0	Cash & ST Invest.	31,608
EBIT - LTM	23,263.0	Total Assets	182,018.0
EBITDA - LTM	30,304.0	Total Debt	34,751.0
Net Income - LTM	19,157.0	Total Liabilities	107,995.0
Total Enterprise Value	460,790	Total Equity	74,023.0
TEV/ Total Revenue	4.4 x	Cash from Operations - LTM	21,576.0
TEV/ EBITDA	14.0 x	Cash From Investing - LTM	-13,334.0
		Cash from Financing -LTM	-14,491.0

**Company Notes**

2016 Q1	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$402.000 from Litigation / Settlement A loss of \$137 from Restructuring A loss of \$66 from Litigation	2014 A1	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$1,899.00 from sale of business A loss of \$1,253.000 from Legal Expense A loss of \$754.000 from Merger/Acquisition Expense A loss of \$346.000 from Other One Time Items A loss of \$178.000 from acquired in R&D
2015 A1	GAAP Net Income includes: (in millions, pre-tax): a total loss of \$1,237.000	2014 Q4	GAAP Net Income Includes: (in millions, pre-tax) A loss of \$692.000 from Legal/Litigation A loss of \$325.000 from Merger/Acquisition Expense A loss of \$156.000 from Acquired In-Process RD A loss of \$49.000 from Sale of Business
2015 Q4	GAAP Net Income includes: (in millions, pre-tax): a loss of \$214.000 from Acquired In-Process R&D Expense a gain of \$33.000 from Sale of Business a loss of \$590.000 from Restructuring Charges a loss of \$83.000 from Other One-Time Charges	2015 Q3	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$1948.000 from Sale of Business A loss of \$346.000 from Other One Time Items A loss of \$285.000 from Legal Expense A loss of \$167.000 from Merger/Acquisition Expense
2015 Q3	GAAP Net Income Includes: (in millions, pre-tax) A loss of \$409.000 from Legal Expense A loss of \$32.000 from Merger/Acquisition Expense A loss of \$10.000 from Acquired In-Process RD	2015 Q2	GAAP Net Income Includes: (in millions, pre-tax) A gain of \$134.000 from Legal Expense A loss of \$49.000 from Merger/Acquisition Expense A loss of \$9.000 from Other One Time Items A gain of \$3.000 from Sale of Business
2015 Q2	GAAP Net Income Includes: (in millions, pre-tax) A loss of \$134.000 from Legal Expense A loss of \$49.000 from Merger/Acquisition Expense A loss of \$9.000 from Other One Time Items A gain of \$3.000 from Sale of Business	2015 Q1	2014 Q2


**Key Board Members**

Name	Title	Organization
Anne M Mulcahy	Partner Board Member Board Member Lead Director	Lead Edge Capital Graham Holdings Co Lpl Financial Holdings Inc Johnson & Johnson
Mark A Weinberger	Co-Founder Senior Advisor Board Member Board Member Board Member Board Member Board Member Trustee Board Member Trustee	Washington Counsel Pc Stone Canyon Industries Holdin Accelerate Acquisition Corp Saudi Arabian Oil Co Johnson & Johnson Metlife Inc Concord Coalition National Bureau Of Economic Re United States Council For Inte Bullis School
Hubert Joly	Lead Director Board Member Board Member	Case Western Reserve Universit Ralph Lauren Corp Johnson & Johnson
Mark B Mcclellan	Board Member Founding Dir:Margolis Center For Senior Advisor Board Member Board Member Board Member Board Member	Minnesota Business Partnership Duke University Blackstone Group Inc Cigna Corp Gary & Mary West Wireless Heal Alignment Healthcare Inc Johnson & Johnson
Ian E L Davis	Board Member Senior Advisor Chairman Board Member Chairman	Arbormetrix Inc Apax Partners Llp Vickers Pension Trustees Ltd Thoughtworks Inc Thoughtworks Holding Inc

Ticker:	JNJ US EQUITY	<b>Johnson &amp; Johnson</b>											
Period Type:	Annuals	Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos											
Annuals													
FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	0FY	-0FQ	1FY	2FY	3FY		


Key Financials	Actuals											LTM		Estimates	
	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/10/2022	02/10/2022	31/12/2022	31/12/2023	31/12/2024				
For the Fiscal Period Ending	USD											USD	USD	USD	USD
<b>Total Revenue</b>	70,074.0	71,890.0	76,450.0	81,581.0	82,059.0	82,584.0	93,775.0	23,791.0	93,775.0	23,885.6	23,885.6				
<i>Growth Over Prior Year</i>	(5.7%)	2.6%	6.3%	6.7%	0.6%	0.6%	13.6%	5.0%	(3.7%)	(3.7%)	(3.7%)				
<b>Gross Profit</b>	48,538.0	50,205.0	51,011.0	54,490.0	54,503.0	54,157.0	63,920.0	64,762.0	--	--	--				
<i>Margin %</i>	69.3%	69.8%	66.7%	66.8%	66.4%	65.6%	68.2%	272.2%	--	--	--				
<b>EBITDA</b>	21,811.0	24,890.0	24,131.0	26,978.0	27,389.0	27,264.0	31,337.0	30,304.0	7,817.3	7,817.3	7,817.3				
<i>Margin %</i>	31.1%	34.6%	31.6%	33.1%	33.4%	33.0%	33.4%	127.4%	8.3%	32.7%	32.7%				
<b>EBIT</b>	18,065.0	21,136.0	18,489.0	20,049.0	20,080.0	19,733.0	23,647.0	23,263.0	6,671.9	6,671.9	6,671.9				
<i>Margin %</i>	25.8%	29.4%	24.2%	24.6%	24.5%	23.9%	25.2%	97.8%	7.1%	27.9%	27.9%				
<b>Earnings from Cont. Ops.</b>	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	19,157.0	--	--	--				
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	80.5%	--	--	--				
<b>Net Income</b>	15,409.0	16,540.0	1,300.0	15,297.0	15,119.0	14,714.0	20,878.0	19,157.0	5,923.1	5,923.1	5,923.1				
<i>Margin %</i>	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	80.5%	6.3%	24.8%	24.8%				
<b>Diluted EPS Excl. Extra Items</b>	5.5	5.9	0.5	5.6	5.6	5.5	7.8	7.2	2.2	2.2	2.2				
<i>Growth Over Prior Year</i>	(3.9%)	8.2%	(92.1%)	1.093.6%	0.4%	(2.1%)	41.7%	7.3%	4.6%	4.6%	4.6%				

Current Capitalization (Millions)	
Currency	USD
Share Price (USD)	177.03
Shares Out.	2,614.48
<b>Market Capitalization (USD)</b>	<b>462,842.03</b>
- Cash & Short Term Investments	34,079.00
+ Total Debt	32,027.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
<b>= Total Enterprise Value (USD)</b>	<b>460,790.03</b>
Book Value of Common Equity	74,599.00
+ Pref. Equity	0.00
+ Total Minority Interest	0.00
+ Total Debt	32,027.00
<b>= Total Capital</b>	<b>106,626.00</b>



Valuation Multiples based on Current Capitalization	Actual		Estimates		
	02/10/2022	02/10/2022	02/10/2022	02/10/2022	02/10/2022
TEV/Total Revenue	4.8x	4.4x	19.2x	19.2x	19.2x
TEV/EBITDA	14.5x	14.0x	13.2x	13.2x	13.2x
TEV/EBIT	19.2x	18.3x	15.2x	15.2x	15.2x
P/Diluted EPS Before Extra	21.9x	22.8x			
P/BV	6.1x	5.7x	5.8x	5.8x	5.8x
Price/Tang BV	--	485.8x			

Valuation Multiples for Chart	For the Fiscal Period Ending			
	TTM	FY1	NTM	FY2
PE Ratio	21.0x	17.6x	17.6x	17.6x
TEV / EBITDA	14.0x	13.2x	13.2x	13.2x
Price / CF	21.7x	15.9x	15.9x	15.9x
Price / Book	6.2x	5.8x	5.8x	5.8x
Dividend Yield	2.5x	2.6x	2.6x	2.6x



Ticker:	JNJ US EQUITY
Period Type	Annuals

JNJ US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Income Statement</b>											
<b>Income Sheet as of:</b>											
<b>Currency</b>	01/01/2012 USD	30/12/2012 USD	29/12/2013 USD	28/12/2014 USD	03/01/2016 USD	01/01/2017 USD	31/12/2017 USD	30/12/2018 USD	29/12/2019 USD	03/01/2021 USD	02/01/2022 USD
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Other Revenue	-	-	-	-	-	-	-	-	-	-	-
<b>Total Revenue</b>	<b>65,030.00</b>	<b>67,224.00</b>	<b>71,312.00</b>	<b>74,331.00</b>	<b>70,074.00</b>	<b>71,890.00</b>	<b>76,450.00</b>	<b>81,581.00</b>	<b>82,059.00</b>	<b>82,584.00</b>	<b>93,775.00</b>
Cost Of Goods Sold	20,360.00	21,658.00	22,342.00	22,746.00	21,536.00	21,685.00	25,439.00	27,091.00	27,556.00	28,427.00	29,855.00
<b>Gross Profit</b>	<b>44,670.00</b>	<b>45,566.00</b>	<b>48,970.00</b>	<b>51,585.00</b>	<b>48,538.00</b>	<b>50,205.00</b>	<b>51,011.00</b>	<b>54,490.00</b>	<b>54,503.00</b>	<b>54,157.00</b>	<b>63,920.00</b>
Selling General & Admin Exp.	21,538.00	22,032.00	22,410.00	22,132.00	21,427.00	19,974.00	21,928.00	23,666.00	23,068.00	22,265.00	25,559.00
R & D Exp.	7,548.00	7,665.00	8,183.00	8,494.00	9,046.00	9,095.00	10,594.00	10,775.00	11,355.00	12,159.00	14,714.00
Depreciation & Amort.	-	-	-	-	-	-	-	-	-	-	-
Other Operating Expense/(Income)	-	-	-	-	-	-	-	-	-	-	-
<b>Operating Expense., Total</b>	<b>29,086.00</b>	<b>29,697.00</b>	<b>30,593.00</b>	<b>30,626.00</b>	<b>30,473.00</b>	<b>29,069.00</b>	<b>32,522.00</b>	<b>34,441.00</b>	<b>34,423.00</b>	<b>34,424.00</b>	<b>40,273.00</b>
<b>Operating Income</b>	<b>15,584.00</b>	<b>15,869.00</b>	<b>18,377.00</b>	<b>20,959.00</b>	<b>18,065.00</b>	<b>21,136.00</b>	<b>18,489.00</b>	<b>20,049.00</b>	<b>20,080.00</b>	<b>19,733.00</b>	<b>23,647.00</b>
Interest Expense	571.00	532.00	482.00	533.00	552.00	726.00	934.00	1,005.00	318.00	201.00	183.00
Interest Income	91.00	64.00	74.00	67.00	128.00	368.00	385.00	611.00	357.00	111.00	53.00
<b>Net Interest Exp.</b>	<b>480.00</b>	<b>468.00</b>	<b>408.00</b>	<b>466.00</b>	<b>424.00</b>	<b>358.00</b>	<b>549.00</b>	<b>394.00</b>	<b>(39.00)</b>	<b>90.00</b>	<b>130.00</b>
Currency Exchange Gains (Loss)	-	-	-	-	-	-	-	-	-	-	-
Other Non-Operating Inc. (Exp.)	1,277.00	574.00	852.00	1,088.00	910.00	863.00	619.00	2,873.00	930.00	3,257.00	1,358.00
<b>EBT Excl. Unusual Items</b>	<b>13,827.00</b>	<b>14,827.00</b>	<b>17,117.00</b>	<b>19,405.00</b>	<b>16,731.00</b>	<b>19,915.00</b>	<b>17,321.00</b>	<b>16,782.00</b>	<b>19,189.00</b>	<b>16,386.00</b>	<b>22,159.00</b>
Impairment of Goodwill	-	-	-	-	-	-	-	-	-	-	-
Gain (Loss) On Sale Of Assets	-	-	-	(2,383.00)	(2,583.00)	(563.00)	(1,307.00)	(1,217.00)	(2,154.00)	(111.00)	(617.00)
Asset Writedown	-	-	-	-	-	-	-	-	-	-	-
Legal Settlements	1,466.00	1,052.00	1,646.00	1,225.00	118.00	675.00	955.00	-	4,015.00	-	-
Other Unusual Items	(2,932.00)	(2,104.00)	(3,292.00)	2,316.00	4,930.00	(224.00)	704.00	2,434.00	(3,722.00)	222.00	1,234.00
<b>EBT Incl. Unusual Items</b>	<b>12,361.00</b>	<b>13,775.00</b>	<b>15,471.00</b>	<b>20,563.00</b>	<b>19,196.00</b>	<b>19,803.00</b>	<b>17,673.00</b>	<b>17,999.00</b>	<b>17,328.00</b>	<b>16,497.00</b>	<b>22,776.00</b>
Income Tax Expense	2,689.00	3,261.00	1,640.00	4,240.00	3,787.00	3,263.00	16,373.00	2,702.00	2,209.00	1,783.00	1,898.00
<b>Earnings from Cont. Ops.</b>	<b>9,672.00</b>	<b>10,514.00</b>	<b>13,831.00</b>	<b>16,323.00</b>	<b>15,409.00</b>	<b>16,540.00</b>	<b>1,300.00</b>	<b>15,297.00</b>	<b>15,119.00</b>	<b>14,714.00</b>	<b>20,878.00</b>
Extraord. Item & Account. Change	-	-	-	-	-	-	-	-	-	-	-
Minority Int. in Earnings	-	(339.00)	-	-	-	-	-	-	-	-	-
<b>Net Income</b>	<b>9,672.00</b>	<b>10,853.00</b>	<b>13,831.00</b>	<b>16,323.00</b>	<b>15,409.00</b>	<b>16,540.00</b>	<b>1,300.00</b>	<b>15,297.00</b>	<b>15,119.00</b>	<b>14,714.00</b>	<b>20,878.00</b>
Pref. Dividends	-	-	-	-	-	-	-	-	-	-	-
Other Adj	-	-	-	-	-	-	-	-	-	-	-
<b>NI to Common Incl Extra Items</b>	<b>9,672.00</b>	<b>10,853.00</b>	<b>13,831.00</b>	<b>16,323.00</b>	<b>15,409.00</b>	<b>16,540.00</b>	<b>1,300.00</b>	<b>15,297.00</b>	<b>15,119.00</b>	<b>14,714.00</b>	<b>20,878.00</b>
Abnormal Losses (Gains)	4,992.00	4,439.00	3,643.00	(1,751.00)	(671.00)	1,685.00	3,752.00	4,270.00	6,413.00	4,713.00	2,991.00
Tax Effect on Abnormal Items	(797.00)	(947.00)	(1,633.75)	984.05	241.85	(342.90)	12,507.00	(1,286.70)	(1,885.07)	(1,371.90)	(1,599.50)
<b>NI to Common Excl. Extra Items</b>	<b>13,867.00</b>	<b>14,345.00</b>	<b>15,840.25</b>	<b>15,556.05</b>	<b>14,979.85</b>	<b>17,882.10</b>	<b>17,559.00</b>	<b>18,280.30</b>	<b>19,646.93</b>	<b>18,055.10</b>	<b>22,269.50</b>
<b>Per Share Items</b>											
Basic EPS	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93
Basic EPS Excl. Extra Items	3.54	3.94	4.92	5.80	5.56	6.04	0.48	5.70	5.72	5.59	7.93
Weighted Avg. Basic Shares Out.	2,736.00	2,753.30	2,809.20	2,815.20	2,771.80	2,737.30	2,692.00	2,681.50	2,645.10	2,632.80	2,632.10
Diluted EPS	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Diluted EPS Excl. Extra Items	3.49	3.86	4.81	5.70	5.48	5.93	0.47	5.61	5.63	5.51	7.81
Weighted Avg. Diluted Shares Out.	2,775.30	2,812.60	2,877.00	2,863.90	2,812.90	2,788.90	2,745.30	2,728.70	2,684.30	2,670.70	2,674.00
Normalized Basic EPS	5.00	5.10	5.52	5.97	6.20	6.73	7.30	8.18	8.68	8.03	9.80
Normalized Diluted EPS	5.00	5.10	5.51	5.43	5.33	6.41	6.39	6.70	7.32	6.76	8.33
Dividends per Share	-	-	-	-	-	-	-	-	-	-	-
Payout Ratio %	63.65	60.89	52.61	47.60	53.07	52.13	687.50	62.05	65.61	71.21	52.82
<b>Supplemental Items</b>											
EBITA	16,442.00	17,035.00	19,781.00	22,354.00	19,311.00	22,390.00	21,531.00	24,378.00	24,889.00	24,664.00	28,637.00
EBIT	15,584.00	15,869.00	18,377.00	20,959.00	18,065.00	21,136.00	18,489.00	20,049.00	20,080.00	19,733.00	23,647.00
As Reported Total Revenue*	65,030.00	-	-	-	-	-	-	81,581.00	82,059.00	82,584.00	93,775.00
Effective Tax Rate %	21.75	23.67	10.60	20.62	19.73	16.48	92.64	15.01	12.75	10.81	8.33
Normalized Net Income	13,867.00	14,345.00	15,840.25	15,556.05	14,979.85	17,882.10	17,559.00	18,280.30	19,646.93	18,055.10	22,269.50
Interest Capitalized	84.00	115.00	105.00	115.00	102.00	102.00	94.00	86.00	70.00	63.00	49.00
<b>Supplemental Operating Expense Items</b>											
Net Rental Exp.	-	-	-	-	-	-	-	-	-	-	-
Stock-Based Comp., Unallocated	621.00	662.00	728.00	792.00	874.00	878.00	962.00	978.00	977.00	1,005.00	1,135.00
<b>Stock-Based Comp., Total</b>	<b>621.00</b>	<b>662.00</b>	<b>728.00</b>	<b>792.00</b>	<b>874.00</b>	<b>878.00</b>	<b>962.00</b>	<b>978.00</b>	<b>977.00</b>	<b>1,005.00</b>	<b>1,135.00</b>

Ticker:	JNJ US EQUITY
Period Type	Annuals

JNJ US EQUITY	Ascend
Consolidated	Yes

Currency	Reporting	Change	USD
Accounting	Mixed		

## Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Balance Sheet</b>											
Balance Sheet as of:	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
<b>ASSETS</b>											
Cash And Equivalents	24,542.00	14,911.00	20,927.00	14,523.00	13,732.00	18,972.00	17,824.00	18,107.00	17,305.00	13,985.00	14,487.00
Short Term Investments	7,719.00	6,178.00	8,279.00	18,566.00	24,644.00	22,935.00	472.00	1,580.00	1,982.00	11,200.00	17,121.00
<b>Total Cash &amp; ST Investments</b>	<b>32,261.00</b>	<b>21,089.00</b>	<b>29,206.00</b>	<b>33,089.00</b>	<b>38,376.00</b>	<b>41,907.00</b>	<b>18,296.00</b>	<b>19,687.00</b>	<b>19,287.00</b>	<b>25,185.00</b>	<b>31,608.00</b>
Accounts & Notes Receivable	10,581.00	11,309.00	11,713.00	10,985.00	10,734.00	11,699.00	13,490.00	14,098.00	14,481.00	13,576.00	15,283.00
<b>Total Receivables</b>	<b>10,581.00</b>	<b>11,309.00</b>	<b>11,713.00</b>	<b>10,985.00</b>	<b>10,734.00</b>	<b>11,699.00</b>	<b>13,490.00</b>	<b>14,098.00</b>	<b>14,481.00</b>	<b>13,576.00</b>	<b>15,283.00</b>
Inventories	6,285.00	7,495.00	7,878.00	8,184.00	8,053.00	8,144.00	8,765.00	8,599.00	9,020.00	9,344.00	10,387.00
Prepaid Exp.	2,633.00	3,084.00	4,003.00	3,486.00	3,047.00	3,282.00	2,537.00	2,699.00	2,392.00	3,132.00	3,701.00
Restricted Cash	-	-	-	-	-	-	-	-	-	-	-
Other Current Assets	2,556.00	3,139.00	3,607.00	-	-	-	-	950.00	94.00	-	-
<b>Total Current Assets</b>	<b>54,316.00</b>	<b>46,116.00</b>	<b>56,407.00</b>	<b>55,744.00</b>	<b>60,210.00</b>	<b>65,032.00</b>	<b>43,088.00</b>	<b>46,033.00</b>	<b>45,274.00</b>	<b>51,237.00</b>	<b>60,979.00</b>
<b>Net Property, Plant &amp; Equipment</b>	<b>14,739.00</b>	<b>16,097.00</b>	<b>16,710.00</b>	<b>16,126.00</b>	<b>15,905.00</b>	<b>15,912.00</b>	<b>17,005.00</b>	<b>17,035.00</b>	<b>18,615.00</b>	<b>18,766.00</b>	<b>18,962.00</b>
Long-term Investments	-	-	-	-	-	-	-	-	-	-	-
Deferred Charges, LT	6,540.00	4,541.00	3,872.00	6,202.00	5,490.00	6,148.00	7,105.00	7,640.00	7,819.00	8,534.00	10,223.00
Other Long-Term Assets	38,049.00	54,593.00	55,694.00	52,286.00	51,806.00	54,116.00	90,105.00	82,246.00	86,020.00	96,357.00	91,854.00
<b>Total Assets</b>	<b>113,644.00</b>	<b>121,347.00</b>	<b>132,683.00</b>	<b>130,358.00</b>	<b>133,411.00</b>	<b>141,208.00</b>	<b>157,303.00</b>	<b>152,954.00</b>	<b>157,728.00</b>	<b>174,894.00</b>	<b>182,018.00</b>
<b>LIABILITIES</b>											
Accrued Exp.	9,574.00	12,691.00	13,787.00	13,314.00	13,325.00	13,714.00	17,467.00	20,079.00	23,952.00	28,965.00	29,293.00
Short-term Borrowings	6,658.00	4,676.00	4,852.00	3,638.00	7,004.00	4,684.00	3,906.00	2,796.00	1,471.00	2,631.00	3,766.00
Accounts Payable	5,725.00	5,831.00	6,266.00	7,633.00	6,668.00	6,918.00	7,310.00	7,537.00	8,544.00	9,505.00	11,055.00
Curr. Income Taxes Payable	854.00	1,064.00	770.00	446.00	750.00	971.00	1,854.00	818.00	2,266.00	1,392.00	1,112.00
Other Current Liabilities	-	-	-	-	-	-	-	-	(269.00)	-	-
<b>Total Current Liabilities</b>	<b>22,811.00</b>	<b>24,262.00</b>	<b>25,675.00</b>	<b>25,031.00</b>	<b>27,747.00</b>	<b>26,287.00</b>	<b>30,537.00</b>	<b>31,230.00</b>	<b>35,964.00</b>	<b>42,493.00</b>	<b>45,226.00</b>
Long-Term Debt	12,969.00	11,489.00	13,328.00	15,122.00	12,857.00	22,442.00	30,675.00	27,684.00	27,210.00	33,735.00	30,985.00
Unearned Revenue, Non-Current	-	-	-	-	-	-	-	-	-	-	-
Other Non-Current Liabilities	20,784.00	20,770.00	19,627.00	20,453.00	21,657.00	22,061.00	35,931.00	34,288.00	35,083.00	35,388.00	31,784.00
<b>Total Liabilities</b>	<b>56,564.00</b>	<b>56,521.00</b>	<b>58,630.00</b>	<b>60,606.00</b>	<b>62,261.00</b>	<b>70,790.00</b>	<b>97,143.00</b>	<b>93,202.00</b>	<b>98,257.00</b>	<b>111,616.00</b>	<b>107,995.00</b>
Pref. Stock, Non-Redeem.	-	-	-	-	-	-	-	-	-	-	-
<b>Total Pref. Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Additional Paid In Capital	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00	3,120.00
Retained Earnings	81,251.00	85,992.00	89,493.00	97,245.00	103,879.00	110,551.00	101,793.00	106,216.00	110,659.00	113,890.00	123,060.00
Treasury Stock	(21,659.00)	(18,476.00)	(15,700.00)	(19,891.00)	(22,684.00)	(28,352.00)	(31,554.00)	(34,362.00)	(38,417.00)	(38,490.00)	(39,099.00)
Comprehensive Inc. and Other	(5,632.00)	(5,810.00)	(2,860.00)	(10,722.00)	(13,165.00)	(14,901.00)	(13,199.00)	(15,222.00)	(15,891.00)	(15,242.00)	(13,058.00)
<b>Total Common Equity</b>	<b>57,080.00</b>	<b>64,826.00</b>	<b>74,053.00</b>	<b>69,752.00</b>	<b>71,150.00</b>	<b>70,418.00</b>	<b>60,160.00</b>	<b>59,752.00</b>	<b>59,471.00</b>	<b>63,278.00</b>	<b>74,023.00</b>
<b>Total Equity</b>	<b>57,080.00</b>	<b>64,826.00</b>	<b>74,053.00</b>	<b>69,752.00</b>	<b>71,150.00</b>	<b>70,418.00</b>	<b>60,160.00</b>	<b>59,752.00</b>	<b>59,471.00</b>	<b>63,278.00</b>	<b>74,023.00</b>
<b>Total Liabilities And Equity</b>	<b>113,644.00</b>	<b>121,347.00</b>	<b>132,683.00</b>	<b>130,358.00</b>	<b>133,411.00</b>	<b>141,208.00</b>	<b>157,303.00</b>	<b>152,954.00</b>	<b>157,728.00</b>	<b>174,894.00</b>	<b>182,018.00</b>
<b>Supplemental Items</b>											
Total Shares Out. on Filing Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97
Total Shares Out. on Balance Sheet Date	2,724.36	2,778.49	2,820.63	2,783.22	2,755.16	2,706.51	2,682.53	2,662.32	2,632.51	2,632.51	2,628.97
Book Value/Share	20.95	23.33	26.25	25.06	25.82	26.02	22.43	22.44	22.59	24.04	28.16
Tangible Book Value	22,804.00	13,650.00	23,308.00	20,698.00	23,757.00	20,737.00	(24,974.00)	(18,312.00)	(21,811.00)	(26,517.00)	(7,615.00)
Tangible Book Value/Share	8.37	4.91	8.26	7.44	8.62	7.66	(9.31)	(6.88)	(8.29)	(10.07)	(2.90)
Total Debt	19,627.00	16,165.00	18,180.00	18,760.00	19,861.00	27,126.00	34,581.00	30,480.00	28,681.00	36,366.00	34,751.00
Net Debt	(12,634.00)	(4,924.00)	(11,026.00)	(14,329.00)	(18,515.00)	(14,781.00)	16,285.00	10,793.00	9,394.00	11,181.00	3,143.00
Total Minority Interest	-	-	-	-	-	-	-	-	-	-	-
Inventories Method	--	--	--	--	--	--	--	--	--	--	--
Raw Materials in Inventory	1,206.00	1,416.00	1,224.00	1,214.00	936.00	952.00	1,140.00	1,114.00	1,117.00	1,410.00	1,592.00
Work in Progress Inventory	1,637.00	2,262.00	2,612.00	2,461.00	2,241.00	2,185.00	2,317.00	2,109.00	1,832.00	2,040.00	2,287.00
Finished Goods Inventory	3,442.00	3,817.00	4,042.00	4,509.00	4,876.00	5,007.00	5,308.00	5,376.00	6,071.00	5,894.00	6,508.00
Other Inventory Accounts	-	-	-	-	-	-	-	-	-	-	-
Accum. Allowance for Doubtful Accts	361.00	466.00	333.00	275.00	268.00	252.00	291.00	248.00	226.00	293.00	230.00
Full Time Employees	117,900.00	127,600.00	128,100.00	126,500.00	127,100.00	126,400.00	134,000.00	135,100.00	132,200.00	134,500.00	144,300.00



Ticker: JNJ US EQUITY  
 Period Type: Annuals

Sort: Ascend  
 Consolidated: Yes

Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

		-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
Multiples		01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
TEV / LTM Total Revenue	Close	2.6x	2.8x	3.5x	3.7x	3.8x	4.1x	5.1x	4.3x	4.8x	5.2x	4.8x
	Average	2.6x	2.6x	3.5x	3.8x	3.5x	4.2x	4.7x	4.9x	4.5x	4.8x	5.4x
	High	2.8x	2.9x	3.9x	4.1x	3.8x	4.7x	5.2x	5.4x	4.9x	5.2x	5.9x
	Low	2.4x	2.4x	2.8x	3.3x	3.2x	3.5x	4.0x	4.3x	4.2x	3.7x	4.8x
TEV / LTM EBITDA	Close	8.9x	9.6x	11.1x	11.2x	12.1x	11.9x	16.2x	13.0x	14.4x	15.6x	14.5x
	Average	8.4x	9.2x	12.0x	12.1x	10.6x	13.4x	13.5x	15.5x	13.7x	14.4x	16.4x
	High	9.0x	10.0x	13.6x	13.1x	12.2x	15.0x	16.2x	17.2x	14.7x	15.6x	17.7x
	Low	7.5x	8.4x	9.7x	10.4x	9.5x	11.3x	11.6x	13.1x	12.8x	11.0x	14.5x
TEV / LTM EBIT	Close	10.7x	11.9x	13.6x	13.3x	14.6x	14.1x	21.2x	17.4x	19.5x	21.6x	19.2x
	Average	9.9x	11.0x	14.8x	14.8x	12.5x	16.2x	15.9x	20.2x	18.4x	19.6x	22.6x
	High	10.7x	12.0x	16.7x	16.1x	14.7x	18.1x	21.2x	22.4x	19.8x	21.6x	24.5x
	Low	8.9x	10.1x	11.9x	12.7x	11.3x	13.6x	13.7x	17.6x	17.2x	15.0x	19.2x
Price / LTM EPS	Close	13.1x	13.6x	16.8x	19.3x	19.3x	18.0x	21.9x	19.0x	19.9x	23.3x	20.5x
	Average	13.3x	13.4x	16.8x	18.3x	18.4x	21.3x	20.2x	20.8x	20.1x	19.9x	24.5x
	High	14.3x	14.5x	18.7x	19.8x	19.6x	23.5x	22.4x	23.2x	21.8x	23.3x	26.5x
	Low	12.1x	12.4x	13.7x	15.7x	16.7x	18.0x	17.4x	18.7x	18.8x	15.2x	20.5x
Price / Book Value	Close	3.1x	3.0x	3.5x	4.2x	4.0x	4.4x	6.2x	5.7x	6.5x	6.5x	6.1x
	Average	3.1x	3.2x	3.7x	3.8x	4.0x	4.4x	5.0x	5.9x	6.0x	6.5x	6.9x
	High	3.3x	3.5x	4.1x	4.2x	4.2x	4.9x	6.2x	6.6x	6.5x	6.9x	7.5x
	Low	2.8x	2.9x	3.0x	3.3x	3.6x	3.7x	4.3x	5.3x	5.6x	4.9x	6.1x
Price / Tangible Book Value	Close	7.8x	14.1x	11.2x	14.1x	11.9x	15.0x	--	--	--	--	--
	Average	7.1x	8.0x	17.4x	12.2x	13.4x	13.2x	16.9x	--	--	--	--
	High	7.8x	14.1x	19.5x	14.1x	14.3x	15.0x	18.7x	--	--	--	--
	Low	6.4x	7.4x	11.2x	10.5x	11.9x	11.1x	14.6x	--	--	--	--
Price / Cash Flow	Close	12.5x	12.4x	14.9x	15.8x	14.5x	16.8x	17.9x	15.4x	16.5x	17.6x	19.2x
	Average	10.7x	12.8x	15.3x	16.2x	15.0x	16.1x	18.9x	17.0x	16.3x	16.5x	18.5x
	High	12.5x	13.9x	17.1x	17.6x	16.0x	17.8x	20.9x	18.9x	17.7x	17.6x	20.1x
	Low	9.7x	11.8x	12.5x	14.0x	13.7x	13.6x	16.3x	15.3x	15.2x	12.6x	17.1x
TEV / LTM FCF	Close	15.7x	15.4x	18.8x	19.7x	17.7x	20.3x	21.2x	18.4x	19.4x	20.5x	22.8x
	Average	12.5x	16.1x	18.9x	20.5x	18.7x	19.6x	22.8x	20.1x	19.5x	19.4x	21.6x
	High	15.7x	17.4x	21.1x	22.2x	20.0x	21.6x	25.3x	22.4x	21.2x	20.7x	23.4x
	Low	11.3x	14.8x	15.5x	17.6x	17.0x	16.5x	19.7x	18.1x	18.2x	14.8x	20.0x
Dividend Yield	Close	3.4	3.5	2.8	2.6	2.9	2.7	2.4	2.8	2.6	2.5	2.4
	Average	3.3	3.4	2.8	2.6	2.8	2.6	2.4	2.5	2.6	2.6	2.4
	High	3.7	3.6	3.4	3.0	3.0	3.1	2.8	2.8	2.8	3.4	2.6
	Low	3.1	3.1	2.5	2.4	2.6	2.4	2.2	2.2	2.4	2.4	2.2

Ticker:	JNJ US EQUITY
Period Type:	Quarters

JNJ US EQUITY	Ascend
Consolidated	Yes

Accounting	Mixed
------------	-------

## Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

Y	-10FQ	-9FQ	-8FQ	-7FQ	-6FQ	-5FQ	-4FQ	-3FQ	-2FQ	-1FQ	-0FQ
Ratios											
For the Fiscal Period Ending	29/03/2020	28/06/2020	27/09/2020	03/01/2021	04/04/2021	04/07/2021	03/10/2021	02/01/2022	03/04/2022	03/07/2022	02/10/2022
<b>Profitability</b>											
Return on Assets	11.3%	9.7%	10.4%	8.8%	9.2%	10.6%	10.2%	11.7%	11.3%	10.4%	10.8%
Return on Capital	19.5%	16.7%	18.0%	15.9%	16.3%	18.3%	17.5%	20.2%	19.2%	17.4%	18.3%
Return on Equity	28.6%	24.5%	27.7%	24.0%	23.8%	26.8%	26.5%	30.4%	28.2%	25.2%	26.4%
<b>Margin Analysis</b>											
Gross Margin	65.9%	64.1%	66.9%	65.2%	68.4%	67.5%	68.9%	67.9%	67.6%	67.0%	67.2%
SG&A Margin	25.1%	27.2%	25.7%	28.7%	24.3%	26.0%	25.7%	28.8%	25.3%	25.9%	25.6%
EBITDA Margin	34.7%	33.9%	33.5%	32.7%	33.1%	33.9%	33.1%	33.1%	31.7%	31.3%	31.6%
EBIT Margin	26.0%	25.0%	24.7%	23.9%	24.4%	25.5%	24.9%	25.2%	24.0%	23.8%	24.2%
Earnings from Cont. Ops Margin	28.3%	22.1%	27.0%	18.4%	29.8%	26.8%	24.7%	20.1%	24.8%	25.7%	26.5%
Net Income Margin	28.0%	19.8%	16.9%	7.7%	27.8%	26.9%	15.7%	19.1%	22.0%	20.0%	18.7%
Normalized Net Income Margin	26.3%	19.3%	24.6%	17.8%	26.4%	24.0%	25.6%	18.9%	25.8%	24.9%	24.3%
Free Cash Flow Margin	13.2%	15.2%	36.3%	31.2%	15.2%	19.3%	32.3%	17.4%	14.4%	19.6%	22.4%
<b>Asset Turnover</b>											
Total Asset Turnover	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x	0.5x
Fixed Asset Turnover	4.7x	4.5x	4.5x	4.4x	4.7x	4.9x	5.0x	5.0x	5.1x	5.2x	5.2x
Accounts Receivable Turnover	5.7x	5.5x	5.5x	5.9x	5.6x	6.0x	6.2x	6.5x	6.2x	6.2x	6.2x
Inventory Turnover	3.1x	3.0x	3.0x	3.1x	3.0x	3.0x	3.0x	3.0x	2.9x	2.9x	2.8x
<b>Short Term Liquidity</b>											
Current Ratio	1.3x	1.2x	1.5x	1.2x	1.3x	1.4x	1.3x	1.3x	1.4x	1.4x	1.4x
Quick Ratio	1.0x	0.9x	1.2x	0.9x	1.0x	1.0x	1.0x	1.0x	1.1x	1.1x	1.1x
Cash from Ops. To Curr Liab	0.5x	0.5x	0.8x	0.6x	0.6x	0.7x	0.7x	0.7x	0.7x	0.7x	0.7x
Ave. Davs Sales Out.	63.8x	66.2x	66.1x	63.0x	65.7x	61.4x	59.8x	56.0x	58.6x	59.0x	58.4x
Ave. Davs Inventory Out.	116.7x	123.0x	123.1x	119.8x	122.8x	123.0x	124.8x	120.3x	125.4x	127.6x	128.4x
Ave. Davs Pavaible Out.	93.9x	89.5x	93.9x	116.5x	100.0x	95.3x	97.3x	171.1x	103.1x	104.8x	106.8x
Ave. Cash Conversion Cycle	86.6x	99.7x	95.4x	66.4x	88.4x	89.1x	87.3x	55.2x	80.8x	81.8x	79.9x
<b>Long Term Solvency</b>											
Total Debt/Equity	45.0%	48.3%	58.6%	57.5%	51.1%	48.1%	48.3%	46.9%	44.4%	42.7%	42.9%
Total Debt/Capital	31.0%	32.6%	36.9%	36.5%	33.8%	32.5%	32.6%	31.9%	30.7%	29.9%	30.0%
LT Debt/Equity	41.4%	39.8%	50.7%	53.3%	46.0%	43.6%	42.9%	41.9%	38.6%	37.1%	37.0%
LT Debt/Capital	28.6%	26.8%	32.0%	33.9%	30.4%	29.4%	28.9%	28.5%	26.7%	26.0%	25.9%
Total Liabilities/Total Assets	38.7%	37.0%	39.5%	39.5%	38.1%	38.6%	35.9%	34.5%	33.8%	31.8%	31.4%
EBIT / Interest Exp.	233.84x	90.02x	129.57x	47.53x	105.52x	156.45x	288.30x	82.92x	581.80x	162.42x	123.49x
EBITDA / Interest Fxn.	303.72x	178.38x	170.89x	69.83x	135.59x	202.43x	379.00x	113.63x	758.70x	208.32x	156.53x
(EBITDA-CAPEX) / Interest Exp.	278.72x	113.67x	154.14x	54.62x	124.84x	182.10x	341.65x	90.05x	698.00x	185.61x	137.86x
Total Debt/EBITDA	0.96x	1.11x	1.39x	1.35x	1.20x	1.11x	1.12x	1.12x	1.10x	1.09x	1.06x
Net Debt/EBITDA	0.33x	0.41x	0.26x	0.41x	0.32x	0.27x	0.10x	0.10x	0.09x	0.00x	-0.07x
Altman Z Score	6.45	6.4	5.86	5.96	6.25	6.38	6.02	6.12	6.4	6.46	6.27
<b>Growth Over Prior Year</b>											
Total Revenue	3.3%	(10.8%)	1.7%	8.3%	7.9%	27.1%	10.7%	10.4%	5.0%	3.0%	1.9%
Gross Profit	1.7%	(13.7%)	1.8%	7.7%	12.0%	33.8%	14.0%	14.9%	3.7%	2.4%	(0.6%)
EBITDA	21.0%	(19.4%)	(2.6%)	(2.6%)	12.5%	40.2%	0.8%	12.2%	(11.2%)	(2.2%)	5.3%
FRITA	23.4%	(21.3%)	(3.5%)	(3.5%)	17.9%	44.1%	0.6%	13.4%	(11.9%)	(2.5%)	6.0%
EBIT	31.7%	(25.1%)	(3.2%)	(4.8%)	13.7%	54.5%	1.1%	20.3%	(12.5%)	(1.4%)	9.2%
Earnings from Cont. Ops.	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.2%	172.5%	(16.9%)	(23.3%)	21.6%
Net Income	54.6%	(35.3%)	102.7%	(56.7%)	6.9%	73.1%	3.2%	172.5%	(16.9%)	(23.3%)	21.6%
Normalized Net Income	13.0%	(40.8%)	8.6%	(5.2%)	8.2%	58.0%	15.2%	17.2%	2.6%	7.1%	(3.1%)
Diluted EPS before Extra	56.1%	(34.6%)	101.5%	(56.7%)	6.9%	72.8%	3.0%	172.3%	(16.8%)	(23.4%)	22.6%
Accounts Receivable	5.4%	(0.1%)	(1.5%)	(6.2%)	0.4%	1.5%	2.3%	12.6%	4.4%	8.5%	6.6%
Inventory	(2.4%)	1.7%	4.6%	3.6%	12.2%	7.2%	8.2%	11.2%	10.4%	13.2%	12.4%
Net PP&E	(2.7%)	(3.5%)	(0.9%)	0.8%	5.6%	5.9%	3.5%	1.0%	1.8%	(1.5%)	(1.8%)
Total Assets	3.3%	2.1%	9.8%	10.9%	11.3%	11.4%	5.0%	4.1%	3.4%	0.7%	(2.3%)
Tangible Book Value	1.5%	(17.2%)	(26.6%)	21.6%	7.4%	(10.0%)	(22.4%)	(71.2%)	(77.8%)	(98.7%)	(106.8%)
Common Equity	4.0%	3.6%	10.8%	6.4%	7.4%	10.5%	9.0%	17.0%	13.5%	9.7%	6.2%
Cash from Ops.	(5.7%)	(42.0%)	11.4%	30.4%	21.3%	53.9%	(1.1%)	(31.3%)	(2.3%)	5.0%	(24.2%)
Capital Expenditures	(4.7%)	(20.9%)	(1.1%)	5.0%	8.3%	22.8%	1.4%	7.0%	(10.3%)	6.2%	27.4%
Levered Free Cash Flow	(5.3%)	(45.4%)	12.7%	36.6%	24.3%	61.3%	(1.3%)	(38.5%)	(0.7%)	4.8%	(29.3%)
Unlevered Free Cash Flow	(53.6%)	(94.9%)	16.4%	65.4%	223.7%	1.205.3%	(4.7%)	(65.0%)	(20.7%)	2.2%	(50.3%)
Dividend per Share	12.2%	11.6%	6.3%	4.7%	0.0%	0.0%	5.0%	6.5%	5.0%	6.6%	6.6%

**CAGR Over Two Years**

Total Revenue	1.7%	(6.2%)	1.8%	5.0%	5.6%	6.5%	6.1%	9.3%	6.4%	14.5%	6.2%
Gross Profit	0.9%	(8.0%)	1.3%	4.5%	6.7%	7.4%	7.7%	11.3%	7.8%	17.0%	6.4%
EBITDA	0.8%	(10.7%)	9.1%	1.0%	16.7%	6.3%	(0.9%)	4.5%	(0.0%)	17.1%	3.0%
EBITA	0.9%	(11.5%)	10.2%	0.7%	18.0%	6.5%	(1.4%)	4.6%	(0.3%)	18.5%	3.3%
FRIT	1.0%	(14.3%)	11.5%	(1.0%)	22.4%	7.6%	(1.0%)	7.0%	(0.2%)	23.4%	5.1%
Earnings from Cont. Ops.	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%	(5.7%)	15.2%	12.0%
Net Income	15.2%	(4.2%)	(5.0%)	(24.4%)	28.6%	5.8%	44.6%	8.7%	(5.7%)	15.2%	12.0%
Normalized Net Income	8.3%	(13.7%)	5.9%	(4.8%)	10.6%	(3.3%)	11.8%	5.4%	5.3%	30.1%	5.7%
Diluted EPS before Extra	16.5%	(3.2%)	(3.9%)	(23.8%)	29.2%	6.3%	44.1%	8.6%	(5.7%)	15.0%	12.4%
Accounts Receivable	2.5%	1.9%	1.9%	(1.9%)	2.9%	0.7%	0.4%	2.7%	2.4%	5.0%	4.4%
Inventory	(0.8%)	3.4%	5.2%	4.2%	4.7%	4.4%	6.4%	7.3%	11.3%	10.2%	10.3%
Net PP&F	1.1%	2.9%	3.6%	5.0%	1.4%	1.1%	1.3%	0.9%	3.7%	2.1%	0.8%
Total Assets	(0.5%)	1.0%	4.7%	6.9%	7.2%	6.7%	7.4%	7.4%	7.3%	5.9%	1.3%
Tangible Book Value	(0.9%)	3.3%	8.0%	21.0%	4.4%	(13.7%)	(24.5%)	(40.9%)	(51.2%)	(89.1%)	--
Common Equity	(1.6%)	0.1%	(0.1%)	2.9%	5.7%	7.0%	9.9%	11.6%	10.4%	10.1%	7.6%
Cash from Ops.	(3.5%)	(24.6%)	15.6%	15.6%	7.2%	(5.5%)	4.9%	(5.3%)	8.9%	27.2%	(13.4%)
Capital Expenditures	(2.5%)	(13.0%)	(5.1%)	0.2%	1.6%	(1.4%)	0.1%	6.0%	(1.5%)	14.2%	13.7%
Levered Free Cash Flow	(3.7%)	(26.8%)	18.4%	19.4%	8.5%	(6.2%)	5.5%	(8.3%)	11.1%	30.0%	(16.5%)
Unlevered Free Cash Flow	(4.2%)	(78.3%)	28.1%	31.7%	22.6%	(18.7%)	5.3%	(23.9%)	60.2%	265.2%	(31.2%)
Dividend per Share	9.7%	8.5%	5.9%	5.1%	5.9%	5.6%	5.6%	5.6%	2.4%	3.2%	5.8%

**CAGR Over Three Years**

Total Revenue	5.2%	(0.9%)	2.4%	3.6%	3.7%	3.8%	4.7%	6.7%	5.4%	5.3%	4.7%
Gross Profit	3.3%	(3.3%)	3.5%	4.3%	4.4%	4.2%	5.4%	7.8%	5.7%	5.7%	4.9%
FRITDA	5.7%	(4.1%)	5.4%	8.9%	4.6%	3.8%	6.3%	4.6%	6.5%	3.4%	1.1%
EBITDA	6.0%	(4.2%)	5.9%	11.1%	4.7%	4.1%	6.9%	4.8%	7.1%	3.4%	1.0%
EBIT	1.9%	(9.2%)	6.5%	13.3%	5.1%	4.3%	8.0%	5.7%	9.4%	4.5%	2.3%
Earnings from Cont. Ops.	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%	11.2%	(5.0%)	36.5%
Net Income	9.4%	(1.8%)	(1.9%)	(154.5%)	12.4%	16.7%	(2.3%)	15.9%	11.2%	(5.0%)	36.5%
Normalized Net Income	4.3%	(8.8%)	6.6%	1.3%	8.3%	5.5%	8.9%	2.1%	7.8%	0.1%	6.6%
Diluted EPS before Extra	10.5%	(1.0%)	(1.0%)	(154.6%)	13.2%	17.5%	(1.6%)	16.5%	11.6%	(4.7%)	36.5%
Accounts Receivable	6.5%	3.3%	3.5%	0.2%	1.8%	1.8%	2.0%	2.7%	3.4%	3.3%	2.4%
Inventory	(0.0%)	(1.0%)	0.3%	2.2%	3.4%	4.7%	6.2%	6.5%	6.5%	7.3%	8.4%
Net PP&E	2.4%	2.3%	2.4%	3.3%	2.5%	3.9%	3.6%	3.6%	1.5%	0.2%	0.3%
Total Assets	2.3%	1.7%	3.1%	3.6%	3.3%	4.3%	4.8%	6.0%	5.9%	4.6%	4.0%
Tangible Book Value	(207.6%)	9.5%	13.0%	2.7%	1.8%	(1.4%)	(3.2%)	(25.0%)	(37.7%)	(78.6%)	(133.8%)
Common Equity	(4.5%)	(4.3%)	(4.5%)	1.7%	1.3%	3.4%	2.8%	7.4%	8.2%	7.9%	8.6%
Cash from Ops.	4.9%	(15.7%)	10.2%	11.0%	4.2%	(4.4%)	9.7%	(2.8%)	3.9%	(2.1%)	(5.8%)
Capital Expenditures	3.7%	(1.3%)	(2.3%)	2.2%	1.0%	(2.4%)	(3.0%)	2.4%	(2.6%)	1.0%	8.5%
Levered Free Cash Flow	5.1%	(18.1%)	11.8%	13.0%	4.8%	(4.7%)	11.4%	(4.3%)	5.3%	(2.6%)	(7.7%)
Unlevered Free Cash Flow	7.8%	(64.1%)	15.7%	18.7%	2.0%	(15.0%)	16.1%	(15.3%)	6.0%	(12.3%)	(18.0%)
Dividend per Share	8.1%	8.1%	6.3%	5.8%	6.3%	5.6%	5.6%	5.6%	5.6%	6.0%	6.0%

**CAGR Over Five Years**

Total Revenue	3.6%	0.6%	4.3%	4.8%	5.0%	4.8%	5.5%	6.5%	5.7%	5.0%	3.9%
Gross Profit	2.4%	(1.1%)	3.5%	3.8%	4.7%	3.6%	5.5%	6.0%	5.1%	4.4%	4.7%
EBITDA	4.0%	(0.1%)	6.2%	7.7%	6.1%	4.2%	3.8%	3.7%	3.3%	3.8%	4.4%
EBITA	4.2%	(0.2%)	5.5%	9.1%	6.5%	4.4%	4.0%	4.1%	3.4%	4.3%	4.8%
EBIT	1.8%	(3.8%)	4.2%	5.5%	4.0%	2.0%	1.4%	1.5%	1.0%	2.7%	6.0%
Earnings from Cont. Ops.	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%	3.1%	4.7%	3.4%
Net Income	6.1%	(4.3%)	1.1%	(11.6%)	6.8%	9.5%	(3.0%)	4.4%	3.1%	4.7%	3.4%
Normalized Net Income	5.5%	(2.1%)	6.5%	(0.2%)	4.8%	3.9%	6.6%	2.5%	4.7%	5.1%	6.2%
Diluted EPS before Extra	7.2%	(3.3%)	2.1%	(10.8%)	7.8%	10.4%	(2.2%)	5.1%	3.7%	5.2%	4.2%
Accounts Receivable	5.2%	4.1%	5.1%	4.8%	5.5%	4.3%	4.8%	5.5%	4.9%	4.0%	3.9%
Inventory	1.9%	2.6%	3.2%	3.0%	4.0%	3.5%	4.1%	5.0%	4.4%	3.4%	4.2%
Net PP&E	2.5%	2.5%	2.8%	3.4%	2.8%	3.1%	2.8%	3.6%	2.9%	2.2%	1.8%
Total Assets	3.8%	3.7%	5.1%	5.6%	4.8%	4.8%	5.0%	5.2%	4.2%	3.1%	2.4%
Tangible Book Value	(201.1%)	(196.9%)	(193.9%)	(203.2%)	(197.4%)	(193.0%)	(190.8%)	(182.3%)	(178.4%)	(56.5%)	(159.7%)
Common Equity	(2.0%)	(2.4%)	(2.1%)	(2.3%)	(2.0%)	(0.8%)	(0.7%)	1.0%	1.2%	1.2%	0.2%
Cash from Ops.	3.2%	(4.9%)	3.2%	10.4%	13.2%	3.1%	9.1%	(2.9%)	6.4%	(0.7%)	0.1%
Capital Expenditures	2.9%	(2.9%)	(1.4%)	(0.6%)	1.2%	1.4%	0.3%	5.3%	1.6%	4.6%	3.8%
Levered Free Cash Flow	3.3%	(5.3%)	3.7%	13.5%	17.0%	3.4%	10.3%	(4.9%)	7.5%	(1.5%)	(0.5%)
Unlevered Free Cash Flow	(9.9%)	(39.3%)	3.0%	21.5%	(207.3%)	1.2%	14.3%	(14.8%)	26.3%	(9.1%)	(6.0%)
Dividend per Share	7.6%	7.2%	6.1%	7.3%	6.1%	5.8%	5.8%	5.8%	5.8%	6.1%	6.1%





Ticker: JNJ US EQUITY      JNJ US EQUITY    Ascend      Currency    Reporting    Change    USD  
 Period Type:    Annuals      Consolidated    Yes      Accounting    Mixed

**Johnson & Johnson**

Sector: Salud    Industry: Productos farmacéuticos    Sub-Industry: Productos farmacéuticos

Y	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>REVENUE</b>											
Revenue by Product											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
Pharmaceutical	25,779.00	27,426.00	28,490.00	32,313.00	31,430.00	33,464.00	38,256.00	40,734.00	42,201.00	45,572.00	52,081.00
Medical Devices	24,368.00	25,351.00	28,125.00	27,522.00	25,137.00	25,119.00	26,592.00	26,994.00	25,961.00	22,959.00	27,059.00
Consumer Health	14,883.00	14,447.00	14,697.00	14,496.00	13,507.00	13,307.00	13,602.00	13,853.00	13,897.00	14,053.00	14,635.00
Corporate	-	-	-	-	-	-	-	-	-	-	-
Spine	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-

Revenue by Geography	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
For the Fiscal Period Ending											
Revenue	65,030.00	67,224.00	71,312.00	74,331.00	70,074.00	71,890.00	76,450.00	81,581.00	82,059.00	82,584.00	93,775.00
United States	28,908.00	29,830.00	31,910.00	34,782.00	35,687.00	37,811.00	39,863.00	41,884.00	42,097.00	43,133.00	47,156.00
Europe	17,129.00	16,945.00	18,599.00	18,947.00	15,995.00	15,770.00	17,126.00	18,753.00	18,466.00	18,980.00	23,594.00
-	12,575.00	13,242.00	13,382.00	13,442.00	12,347.00	12,575.00	13,420.00	14,831.00	15,555.00	15,136.00	17,275.00
-	6,418.00	7,207.00	7,421.00	7,160.00	6,045.00	5,734.00	6,041.00	6,113.00	5,941.00	5,335.00	5,750.00
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-
-	-	-	-	-	-	-	-	-	-	-	-

**GROSS PROFIT BEF TAX**

**OPERATING PROFIT BEF TAX**

Ticker: JNJ US EQUITY	Sort Ascend	Currency Reporting Change USD
Period Type: Annuals	Consolidated: Yes	Accounting: Mixed

Johnson & Johnson

Sector: Salud Industry: Productos farmacéuticos Sub-Industry: Productos farmacéuticos

	-10FY	-9FY	-8FY	-7FY	-6FY	-5FY	-4FY	-3FY	-2FY	-1FY	-0FY
<b>Pension</b>											
For the Fiscal Period Ending	01/01/2012	30/12/2012	29/12/2013	28/12/2014	03/01/2016	01/01/2017	31/12/2017	30/12/2018	29/12/2019	03/01/2021	02/01/2022
Currency	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD	USD
<b>Pension Net Periodic Cost</b>											
Service Cost	638.00	722.00	906.00	882.00	1,037.00	949.00	1,080.00	1,283.00	1,163.00	1,380.00	1,421.00
Interest Cost	853.00	878.00	908.00	1,018.00	988.00	927.00	927.00	996.00	1,096.00	955.00	770.00
Expected Return on Plan Assets	(1,108.00)	(1,236.00)	(1,447.00)	(1,607.00)	(1,809.00)	(1,962.00)	(2,041.00)	(2,212.00)	(2,322.00)	(2,461.00)	(2,645.00)
Pension Expense (Income)	781.00	865.00	1,055.00	743.00	971.00	422.00	594.00	923.00	593.00	790.00	623.00
<b>Other Postretirement Cost</b>											
Service Cost	149.00	175.00	196.00	211.00	257.00	224.00	247.00	269.00	274.00	287.00	309.00
Interest Cost	188.00	165.00	151.00	197.00	186.00	158.00	159.00	148.00	185.00	133.00	81.00
Expected Return on Plan Assets	(1.00)	(4.00)	(6.00)	(7.00)	(7.00)	(6.00)	(6.00)	(7.00)	(6.00)	(7.00)	(7.00)
Other Postretirement Benefits Expense (I)	378.00	409.00	452.00	503.00	604.00	477.00	508.00	502.00	551.00	524.00	503.00
<b>Pension Funded Status</b>											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00
Actual Return (Loss) on Plan Assets	(102.00)	1,926.00	3,573.00	2,078.00	298.00	2,286.00	4,274.00	(1,269.00)	6,185.00	5,524.00	4,439.00
Employer Contribution	1,135.00	1,838.00	565.00	1,176.00	752.00	838.00	664.00	1,140.00	908.00	870.00	969.00
Benefits Paid	(659.00)	(697.00)	(751.00)	(813.00)	(773.00)	(1,210.00)	(1,050.00)	(1,018.00)	(1,555.00)	(1,111.00)	(1,157.00)
Projected Benefit Obligation	17,424.00	21,829.00	21,488.00	26,889.00	25,855.00	28,116.00	33,221.00	31,670.00	37,188.00	43,300.00	41,582.00
Over(Under) Funded Pension	(3,688.00)	(4,293.00)	(587.00)	(4,314.00)	(3,601.00)	(4,483.00)	(4,817.00)	(4,852.00)	(4,987.00)	(5,105.00)	348.00
Accumulated Benefit Obligation	15,452.00	19,267.00	19,203.00	23,816.00	23,262.00	25,319.00	29,793.00	28,533.00	33,416.00	40,356.00	39,049.00
Pension Funding Ratio	78.83	80.33	97.27	83.96	86.07	84.06	85.50	84.68	86.59	88.21	100.84
<b>Other Postretirement Funded Status</b>											
Fair Value of Plan Assets	8.00	122.00	87.00	79.00	74.00	75.00	281.00	180.00	115.00	90.00	102.00
Actual Return (Loss) on Plan Assets	(1.00)	3.00	15.00	8.00	1.00	7.00	12.00	-	19.00	14.00	17.00
Employer Contribution	315.00	543.00	323.00	477.00	414.00	372.00	545.00	282.00	347.00	357.00	343.00
Benefits Paid	(320.00)	(432.00)	(373.00)	(493.00)	(420.00)	(378.00)	(351.00)	(383.00)	(431.00)	(396.00)	(348.00)
Projected Benefit Obligation	3,790.00	4,159.00	4,407.00	5,081.00	4,669.00	4,605.00	4,582.00	4,480.00	5,076.00	5,028.00	4,878.00
Over(Under) Funded Post Ret Benefits	(3,782.00)	(4,037.00)	(4,320.00)	(5,002.00)	(4,595.00)	(4,530.00)	(4,301.00)	(4,300.00)	(4,961.00)	(4,938.00)	(4,776.00)
Other Post-Retirement Funding Ratio	0.21	2.93	1.97	1.55	1.58	1.63	6.13	4.02	2.27	1.79	2.09
<b>Actuarial Assumptions</b>											
<b>Pension</b>											
Expected Return on Plan Assets	8.44	8.45	8.46	8.46	8.53	8.55	8.43	8.46	8.31	8.12	7.71
Discount Rate used on Plan Liabilities	5.08	4.25	4.78	3.78	4.11	3.78	3.30	3.76	2.91	2.14	2.49
Rate of Compensation Increase	4.15	4.08	4.08	4.08	4.05	4.02	4.01	3.98	3.99	4.00	4.01
<b>Other Postretirement Benefits</b>											
Expected Return on Plan Assets	9.00	--	--	--	--	--	--	--	--	--	--
Discount Rate used on Plan Liabilities	5.43	4.55	5.25	5.25	4.31	4.77	4.63	3.85	3.39	2.23	2.68
Health Care Cost Trend Projected(next y)	7.50	6.50	6.50	6.00	6.60	6.32	6.33	6.12	5.87	5.68	5.33
<b>Pension Plan Asset Allocation</b>											
Fair Value of Plan Assets	13,736.00	17,536.00	20,901.00	22,575.00	22,254.00	23,633.00	28,404.00	26,818.00	32,201.00	38,195.00	41,930.00
Asset Category - Equities %	48.78	46.24	50.49	77.00	79.00	75.00	76.00	71.00	74.00	66.00	65.00
Asset Category - Debt %	8.12	9.39	5.82	23.00	21.00	25.00	24.00	29.00	26.00	34.00	35.00
Asset Category - Real Estate %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Company Stock %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Cash %	--	--	--	--	--	--	--	--	--	--	--
Asset Category - Other %	43.10	44.37	43.69	-	-	-	-	-	-	-	-
<b>Expected Pension Payments</b>											
Year 1	354.00	316.00	778.00	793.00	839.00	897.00	970.00	1,062.00	1,126.00	1,257.00	1,317.00
Year 2	277.00	221.00	794.00	813.00	872.00	908.00	1,007.00	1,104.00	1,172.00	1,292.00	1,386.00
Year 3	216.00	220.00	840.00	868.00	911.00	958.00	1,057.00	1,182.00	1,234.00	1,388.00	1,421.00
Year 4	218.00	220.00	890.00	907.00	967.00	1,010.00	1,131.00	1,257.00	1,323.00	1,424.00	1,496.00
Year 5	218.00	220.00	933.00	963.00	1,031.00	1,081.00	1,190.00	1,332.00	1,359.00	1,494.00	1,572.00
Beyond Year 5	1,112.00	1,121.00	6,071.00	5,858.00	6,098.00	6,416.00	7,062.00	7,679.00	7,945.00	8,795.00	9,279.00
<b>Expected Postretirement Benefits</b>											
Year 1	--	--	313.00	316.00	331.00	325.00	322.00	375.00	437.00	427.00	447.00
Year 2	--	--	309.00	309.00	322.00	315.00	312.00	397.00	450.00	440.00	459.00
Year 3	--	--	305.00	306.00	315.00	311.00	306.00	411.00	466.00	453.00	472.00
Year 4	--	--	302.00	303.00	312.00	307.00	301.00	428.00	479.00	465.00	485.00
Year 5	--	--	299.00	300.00	310.00	304.00	297.00	413.00	494.00	417.00	434.00
Beyond Year 5	--	--	1,469.00	1,475.00	1,499.00	1,465.00	1,395.00	2,273.00	2,356.00	2,273.00	2,379.00

